Inhibition of TAZ impairs the migration ability of melanoma cells.
TAZ
hippo signaling pathway
melanoma
metastasis
Journal
Open life sciences
ISSN: 2391-5412
Titre abrégé: Open Life Sci
Pays: Poland
ID NLM: 101669614
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
02
2023
revised:
03
05
2023
accepted:
17
05
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Malignant melanoma (MM) is characterized by rapid growth, frequent metastasis, and high mortality. Targeted therapy for MM is still a research hotspot due to the increasing understanding of the hippo pathway. The aim of this study is to investigate the role of transcriptional coactivator with PDZ-binding motif (TAZ) in MM tumorigenesis. Based on the database analysis, we found that the median mRNA expression of TAZ (5.4) was found to be similar to that of YAP (5.5) in 473 human melanoma specimens. However, in 63 MM cell lines, the median expression of TAZ (10.8) was expressed at a higher level than that of YAP (9.5), which was then validated in A375. TAZ down-regulation by siRNA decreased the migration (72%) and invasion (74%) abilities of A375. Furthermore, the down-regulation of TAZ inhibited the proliferation of A375 without affecting apoptosis. We subsequently blocked hippo signaling with verteporfin and found that verteporfin application decreased the number of migrating (63%) and invading (69%) cells, respectively. We further found that Cyr61 declined following TAZ down-regulation. Moreover, TAZ negatively correlates with melanoma patient's overall survival. Our data proved that TAZ contributed to MM metastasis, which might be a potential therapeutic target in the future.
Identifiants
pubmed: 37360787
doi: 10.1515/biol-2022-0633
pii: biol-2022-0633
pmc: PMC10290279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20220633Informations de copyright
© 2023 the author(s), published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest: Authors state no conflict of interest.
Références
J Invest Dermatol. 2014 Jan;134(1):123-132
pubmed: 23897276
J Med Chem. 2018 Jun 28;61(12):5057-5072
pubmed: 29251924
Ann Transl Med. 2021 Jun;9(12):1038
pubmed: 34277838
Pigment Cell Res. 2007 Jun;20(3):216-21
pubmed: 17516929
Theranostics. 2021 Mar 31;11(12):5794-5812
pubmed: 33897882
Biochem Biophys Res Commun. 2015 Aug 7;463(4):638-43
pubmed: 26043698
Crit Rev Oncol Hematol. 2021 Feb;158:103208
pubmed: 33383207
CA Cancer J Clin. 2020 Mar;70(2):78-85
pubmed: 32101327
Cell Death Dis. 2020 Jul 30;11(7):596
pubmed: 32732916
J Cancer. 2019 Jan 1;10(1):1-10
pubmed: 30662519
Exp Biol Med (Maywood). 2021 Apr;246(8):888-896
pubmed: 33307801
Cell Commun Signal. 2018 Apr 25;16(1):18
pubmed: 29695252
Nat Rev Drug Discov. 2020 Jul;19(7):480-494
pubmed: 32555376
Nature. 2022 Oct;610(7930):190-198
pubmed: 36131018
Int J Cancer. 2020 Aug 1;147(3):692-701
pubmed: 31671209
J Cancer Res Clin Oncol. 2018 Dec;144(12):2283-2302
pubmed: 30094536
J Pers Med. 2022 Jun 16;12(6):
pubmed: 35743763
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
J Cancer Res Clin Oncol. 2021 Jun;147(6):1569-1585
pubmed: 33864521
Oncogene. 2020 Jul;39(30):5267-5281
pubmed: 32561850
Trends Cell Biol. 2020 Oct;30(10):764-776
pubmed: 32800658
Theranostics. 2020 Feb 18;10(8):3622-3635
pubmed: 32206112
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33295-33304
pubmed: 33318171
Cancers (Basel). 2020 Dec 07;12(12):
pubmed: 33297432
Nat Rev Mol Cell Biol. 2019 Apr;20(4):211-226
pubmed: 30546055
Diagnostics (Basel). 2021 Jul 26;11(8):
pubmed: 34441278
Annu Rev Biochem. 2019 Jun 20;88:577-604
pubmed: 30566373
J Cell Physiol. 2019 Dec;234(12):22017-22027
pubmed: 31111478
Nat Cancer. 2021 Feb;2(2):174-188
pubmed: 33644767